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Abstract
According to recent reports, some cancer types exhibit
nonrandom allele loss at codon 72 in exon 4 of the
p53 gene [coding for proline (72Pro) or arginine
(72Arg)]. To clarify this phenomenon for colorectal
cancer and to find out if this preferential loss might
have any functional significance, p53 loss of hetero-
zygosity (LOH) and p53 mutations were investigated in
a group of 61 colorectal cancers and 28 liver meta-
stases, and were correlated with clinicopathologic
factors. A comparison of a patient’s blood codon 72
status with a healthy control group did not reveal an
enhanced risk of developing colorectal tumors for
one of the two isoforms. p53-LOH and p53 mutations
were found in 62.2% and 39.4% of primary tumors,
respectively, and in 57.9% and 25% of hepatic meta-
stases, respectively. In 14 heterozygous cases showing
exon 4-LOH, only the 72Pro allele was lost and the
retained 72Arg was preferentially mutated. In general,
p53 mutations were significantly associated with the
72Arg tumor status (P < .001). Distal tumors showed
allelic losses of the p53 gene more commonly than
proximal tumors (P = .054). The prevalence of 72Arg
increased in frequency with higher Dukes stage
(P = .056). We suggest that either the preferential loss
of 72Pro or the mutation of the 72Arg in colorectal
cancer and hepatic metastases is associated with
malignant potential and might reflect carcinogenic
exposure, particularly in the distal part of the large
intestines.
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Introduction
The p53 tumor-suppressor gene, located on chromosome
17p13, is one of the most commonly mutated genes in all
types of cancer [1,2]. To date, several polymorphisms in the
wild-type p53 gene locus have been described [3]. The most
important p53 polymorphism is the restriction fragment
length polymorphism in codon 72 of exon 4 coding for proline
(72Pro: CCC) or arginine (72Arg: CGC). This polymorphism
has been reported to be associated with some tumor types
[Pro: bladder cancer [4], lung cancer [5,6]; Arg: hepatocellular
carcinoma [7], cervical cancer [8], human papillomavirus
(HPV)–associated cervical cancer [9].
Functional differences between the two polymorphic forms
of the wild-type protein have been described previously [2]. The
72Arg form of wild-type p53 was found to be more sensitive to
proteolysis mediated by the E6 protein of the human papillo-
mavirus than the wild-type 72Pro [10]. Moreover, the codon 72
status of tumor-associated p53 mutants decides whether they
form heterodimers with p73 or not [11]. Nonrandom allele loss
at codon 72 has recently been reported for squamous cell
cancers [11–15]. Furthermore, a better clinical response fol-
lowing cisplatin-based chemoradiotherapy has been shown for
advanced head and neck cancers expressing 72Pro mutants in
comparison to those expressing 72Arg mutants [16]. To the
best of our knowledge, data on colorectal cancer are presently
not available. Although there are several studies dealing with
p53 loss of heterozygosity (LOH) [17–21], colon cancers have
not yet been investigated for a preferential loss of one allele.
Exon 4 polymorphism thus appears to be a system that is
useful in double respect, namely, for studying the frequency
of p53-LOH and for addressing the question of polymorphism.
In this study, we used a new rapid one-step real-time polymer-
ase chain reaction (PCR) in a LightCycler to analyze the
polymorphism [15].
This study was conducted: 1) to test the frequency of p53-
LOH and p53 mutations in a group of colorectal carcinomas
and liver metastases, and to correlate the genetic findings with
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clinicopathologic factors; 2) to answer the question of
whether one allele is preferentially lost in the case of LOH;
3) to correlate p53 mutations and p53-LOH with 72Arg
tumor status; and 4) to test the prevalence of p53 polymor-
phism at codon 72 compared to a healthy control group.
Materials and Methods
Primary Tumors
The tumor group included 61 patients who had undergone
colorectomy for sporadic colon cancer over the last 4 years.
The exclusion criteria were familial adenomatous polyposis,
simultaneous occurrence of adenomas, and other previous
or synchronous adenocarcinomas. The average age of the
patients was 63 years (range, 41–89 years). There were
33 males and 28 females. The tumor was localized in the
right colon (cecum, ascending) in 29 cases, in the transverse
colon in 1 case, and in the left colon (descending, sigmoid,
rectum) in 31 cases. Tumors were graded and staged on
routinely processed, formalin-fixed, and paraffin-embedded
tissue samples. Six tumors were staged Dukes A, 13 as
Dukes B, and 42 as Dukes C [22 with Dukes C1 (TN1M0) and
20 with Dukes C2 (TN>1M>0)]. Five tumors were well
differentiated, 47 tumors were moderately differentiated,
and 9 were poorly differentiated adenocarcinomas. Both
blood and tumor tissue were obtained immediately after
surgical resection (tumor tissue was obtained by the pathol-
ogist C.B. from the center of the lesion avoiding necrotic
areas), frozen in liquid nitrogen, and stored at 70jC until
DNA extraction. Hematoxylin and eosin (H&E)–stained sec-
tions obtained from frozen specimens were examined to
verify representativity.
Metastases
We investigated another group of 28 liver metastases. In
six patients, tissues of the metastases and the correspond-
ing primary tumor were available. Blood and tumor tissue
were always collected for DNA analysis. The mean age of
the group with metastases was 61 years (range, 41–78
years). Twenty-two tumors were moderately differentiated,
and six were poorly differentiated.
Normal Control Group
Blood from 85 Central European Caucasians with homo-
geneous age and sex distribution (average, 45.6 years;
range, 22–88 years; 42 males and 43 females) served as
normal control.
DNA Extraction
Tumor and blood DNA were extracted using the protein-
ase K–phenol–chloroform extraction protocol as previously
described [22].
PCR
For PCR of exon 4 of the p53 gene, we used the Light-
Cycler-DNA Master Hybridization Probes Kit (Roche Diag-
nostics, Mannheim, Germany) as described previously by
Schneider-Stock et al. [15]. Briefly, the LCRed hybridization
probe was designed to detect the C-variant. If G is present,
the resulting mismatch with the probe destabilizes the sam-
ple probe hybrid, and this effect is further enhanced by
inserting two additional inositol bases into the probe, yielding
a melting temperature that is lower in mismatched (Tm =
62.5jC) than in normal-matched cases (Tm = 69jC). The
different melting curve profiles (Figure 1) allow for exact
genotyping without post-PCR handling.
p53 Intron 1 Polymorphism
To further enhance the informativity for p53-LOH, a
second p53 polymorphic marker was analyzed. The intron
1 region of the p53 gene [Alu repeat with (AAAAT)n] was
amplified using the following touchdown PCR: 95jC for
5 minutes, 20 cycles of 95jC for 10 seconds, 66jC for
10 seconds, and 72jC for 20 seconds, with a stepwise
decrease of 2jC in each fifth cycle, and, finally, 30 cycles
at 95jC for 45 seconds, 58jC for 1 minute, and 72jC for
1 minute. Primer sequences were sense 5V-ACTCCAGCCT-
GGGCAATAAGAGCT-3V and antisense 5VACAAAACATC-
CCCTACCAAACAGC-3V. An aliquot of the PCR product
was electrophoresed on native 8% polyacrylamide gels,
cross-linked with piperazine diacrylamide, and visualized by
a silver staining method described by Budowle et al. [23].
An allelic loss was considered in cases when, in compar-
ison with nontumor DNA, the signal of a tumor band dis-
appeared, or signal intensity was reduced bymore than 50%.
Evaluation was done twice, visually, or by densitometry
(VDS; Pharmacia Biotech, Uppsala, Sweden) in ambiguous
cases.
p53 Mutation Analysis
Mutations in exons 4 to 8 of the p53 gene were deter-
mined using PCR-SSCP sequencing analysis as described
by Schneider-Stock et al. [24].
Statistics
Statistical analyses were carried out using the chi-square
analysis or Fisher’s exact test in cross-tables and one-way
ANOVA (for comparison of group means). P values less
Figure 1. Visualization of the melting temperature to identify the genotype
variant at codon 72 in exon 4 of the p53 gene. If G (72Arg) is present, the
resulting sample probe mismatch yields a lower melting temperature (62.5jC)
than the normal-matched cases (C: 72Pro, 68.5jC). Two peaks are visible in
heterozygous cases (C/G).
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than .05 were considered statistically significant, and P < .10
was regarded as a statistical trend. All statistical tests were
two-sided. Calculations were carried out by using the SPSS
9.0 software.
Results
The distribution of p53 codon 72 genotypes (Arg/Arg, Arg/
Pro, and Pro/Pro) is discussed as follows.
Control Group Versus Tumor Group (Blood Analysis)
The distribution of the control group was 44.7% for Arg
homozygotes (n = 38), 48.2% for Arg/Pro heterozygotes
(n = 41), and 7.1% for Pro homozygotes (n = 6). The cancer
group (blood) showed a very similar distribution (47.3%
for homozygous Arg, 44.1% for Arg/Pro, and 8.6% for
homozygous Pro; df = 2, v2 = 0.366, P = .833; Table 1).
Primary Tumors Versus Metastases (Tissue Analysis)
72Arg tended to predominate in the group of metasta-
ses (78.6% for metastases versus 57.4% for primary
tumors) and homozygous Pro variants were only rarely
found (P = .148; Table 2).
Correlation with Other Clinicopathologic Data
Dukes A tumors showed a higher frequency of the homo-
zygous Pro variant, whereas there was preference for the
72Arg variant in Dukes B and C tumors (P = .056; Table 2).
There was no significant correlation between codon 72
status and sex, age, localization, and tumor grade.
LOH
Tumor tissue and corresponding blood were collected
from a total of 76 patients. Informativity of exon 4 polymor-
phism were 33 of 76 (43.5%) and 45 of 76 (59.2%) for intron
1 polymorphism. Considering both polymorphisms together,
informativity increased to 73.7% (56 of 76 tumors). Twenty
cases were excluded because of noninformativity for both
polymorphic markers.
Primary Tumors Versus Metastases
Considering the informative cases, 34 of 56 cases
(60.7%) showed allelic losses at the p53 gene [23 of 37
primary tumors (62.2%) and 11 of 19 metastases (57.9%)]
(Table 2). Thus, for the next analyses, the two groups were
pooled and considered together.
Of the 45 informative cases for intron 1 polymorphism, 32
tumors (71.1%) showed allelic losses. Fourteen of 33 infor-
mative cases (45.5%) showed allelic losses for exon 4
polymorphism. All 14 cases with exon 4-LOH exclusively
showed losses of 72Pro, whereas loss of the 72Arg was
never found (Table 3). To validate the new method, all 14
exon 4-LOH cases were confirmed by using the classic
restriction digest with BshI (AGS, Heidelberg, Germany).
There was a significant correlation between exon 4 and
intron 1 polymorphism (P = .041). Five cases (cases 3, 15,
16, 26, and 29) showed partial losses (i.e., both markers
were informative, but only one of both showed LOH). Eleven
cases exhibited LOH in both markers (Figure 2). Examples of
single analyses are given in Figure 2.
Table 1. Comparison of the Codon 72 Status in the Blood of Colorectal
Cancer, Liver Metastases, and the Healthy Control Group.
Genotype Control Group
[n (%)]
Primary Tumors
[n (%)]
Metastases
[n (%)]
P
n 85 57* 26*
Arg/Arg 38 (44.7) 26 (45.6) 13 (50)
Arg/Pro 41 (48.2) 26 (45.6) 12 (46.4) ns
Pro/Pro 6 (7.1) 5 (8.8) 1 (3.6)
In six cases, the primary tumor and the corresponding metastasis were
investigated.
*Blood was collected from 76 patients.
Table 2. Correlation between Genetic and Clinicopathologic Data of Patients with Colorectal Cancer.
Status at Codon 72
Factor Total p53-LOH–Positive
[n (%)]
P n Arg/Arg
[n (%)]
Arg/Pro
[n (%)]
Pro/Pro
[n (%)]
P
Tumor type
Primary 23/37 (62.2) 0.615 61 35 (57.4) 20 (32.8) 6 (9.8) 0.148
Metastasis 11/19 (57.9) 28 22 (78.6) 5 (17.9) 1 (3.6)
Localization
Right/transverse 7/16 (43.7) 0.054 30 16 (53.3) 11 (36.7) 3 (10) 0.853
Left 16/21 (76.2) 31 18 (58.1) 10 (32.3) 3 (10)
Age (years) pos. 63.8 0.764 63.1 64.5 63.2 0.901
neg. 61.9
Sex
Female 14/19 (73.7) 0.184* 28 17 (57.4) 9 (32.1) 2 (7.1) 0.783
Male 9/18 (50) 33 18 (54.5) 11 (33.3) 4 (12.1)
Tumor grade
Well 2/2 (100) 0.320* 5 4 (80) 0 (0) 1 (20) 0.265
Moderate 21/30 (70) 47 27 (57.4) 15 (31.9) 5 (10.6)
Poor 0/5 (0) 9 4 (44.4) 5 (55.6) 0 (0)
Dukes stage
A 3/3 (100) 0.397 6 2 (33.3) 1 (16.7) 3 (50) 0.056*
B 2/4 (50) 13 9 (69.2) 4 (30.8) 0 (0)
C 18/30 (60) 42 24 (57.2) 15 (35.7) 3 (7.1)
*Fisher’s exact test.
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p53 Mutation Status In total, we found p53 mutations in 31
of 89 cases (34.8%) (Figure 3). There were 24 primary
tumors (39.4%) and seven metastases (25%) with p53
mutations.
p53-LOH and p53 Mutations p53-LOH occurred preferen-
tially in tumors with p53 mutations (P = .029; Table 4).
Arg/Pro Status Versus p53-LOH and p53 Mutations As there
was a selective loss of the proline allele in cases of LOH, we
assessed the mutational status of the retained arginine allele
(Table 3, Figure 2). Examining the 33 germline heterozygous
Arg/Pro patients (i.e., 34 tumors), we found that 10 of 14
cases (71.4%) with exon 4-LOH had p53 missense, frame-
shift, or splicing mutations, whereas such mutations oc-
curred in only 2 of 20 cases (10%) without exon 4-LOH
(Table 3). Interestingly, there was a predominance of muta-
tions in codon 175, a common mutation hotspot codon in
colorectal and head and neck cancers [25].
Considering all 89 tumors, p53 mutations were signifi-
cantly correlated with the 72Arg tumor status (P < .001;
Table 5). The seven tumors with germline homozygous Pro/
Pro never showed p53 mutations.
Correlation of p53-LOH with Other Clinicopathologic Data
There was a tendency for distal tumors to show a higher
frequency of p53-LOH than did proximal tumors (43.7% for
proximal vs 76.2% for distal tumors, P = .054). Allelic losses
were not statistically correlated with sex, age, Dukes stage,
and tumor grading (Table 2). In the six cases for which both
Table 3. p53 Status of Tumors in Germline Heterozygous Arg/Pro Patients.
Tumor Number Exon 4 p53 Mutation
p53-LOH Arg/Pro Exon Codon Amino Acid Exchange
1 LOH Arg 4/42 1-bp insertion Frameshift
2 LOH Arg 5/175 CGC to CAC Arg to His
3 LOH Arg 5/175 CGC to CAC Arg to His
4 (M) LOH Arg 5/175 CGC to CAC Arg to His
5 (M) LOH Arg 5/146 1-bp insertion Frameshift
6 LOH Arg 5/135 TGC to TAC Cys to Tyr
7 (M) LOH Arg 8/306 CGA to TGA Arg to stop
8 LOH Arg 8/273 CGT to TGT Arg to Cys
9 het Arg/Pro WT
9A* (M) LOH Arg 8/splice donor G to T Splicing
10 LOH Arg 8/273 CGT to TGT Arg to Cys
11 LOH Arg WT
12 LOH Arg WT
13 LOH Arg WT
14 LOH Arg WT
15 het Arg/Pro 5/175 CGC to CAC Arg to His
16 het Arg/Pro 7/splice acceptor 12-bp deletion Splicing
17 het Arg/Pro WT
18 het Arg/Pro WT
19 het Arg/Pro WT
20 het Arg/Pro WT
21 het Arg/Pro WT
22 het Arg/Pro WT
23 het Arg/Pro WT
24 het Arg/Pro WT
25 het Arg/Pro WT
26 het Arg/Pro WT
27 het Arg/Pro WT
28 het Arg/Pro WT
29 het Arg/Pro WT
30 (M) het Arg/Pro WT
31 (M) het Arg/Pro WT
32 (M) het Arg/Pro WT
33 (M) het Arg/Pro WT
*Primary tumor and metastasis were investigated; M—metastasis; het—heterozygous without LOH; WT—wild type.
Figure 2. Allelic losses at the p53 locus, codon 72 genotype status, and p53 mutations in the 34 LOH-positive colorectal tumors and liver metastases.
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the primary tumor and the corresponding liver metastases
were available, the following observations were made: in one
case, in contrast to the primary tumor, metastasis (A)
showed an additional allelic loss (Table 3, tumor number
9/9A); in two cases, both primary tumor and metastases
showed p53-LOH with p53 mutations (Figure 2, tumor
numbers 34/34A and 35/35A); three cases were noninfor-
mative for the two polymorphic markers used without p53
mutations.
Discussion
In this study, we investigated p53-LOH frequency, p53
mutations, and p53 codon 72 polymorphism in a group of
colorectal carcinomas and colorectal liver metastases. LOH
frequency was similarly distributed (i.e., 62.1% in primary
tumors and 63.2% in hepatic metastases); exon 4-LOH was
associated only with loss of the 72Pro allele. The retained
72Arg was selectively mutated.
Although an association between codon 72 polymorphism
and risk of cancer has been reported, the results with regard
to colorectal carcinomas remain inconclusive [26,27]. Re-
garding blood, we did not observe a significant difference
between colon cancer cases and ethnically matched controls
for the distribution of codon 72 polymorphism. This may be
caused by the relatively small number of cases in our study.
Considering tumor tissue DNA, we found a significantly
higher frequency of the 72Arg in colorectal tumors. There
was an apparent association of the Arg genotype with tumor
progression, with metastases showing a bias toward the Arg
genotype. There was only one metastasis with Pro/Pro
homozygous constitution. This can be easily explained: all
allelic losses at codon 72 of p53 exon 4 were directed toward
the loss of the proline allele.
There are only a few studies reporting preferential reten-
tion of 72Arg in squamous cell carcinomas of the vulva [12],
head and neck [15], and esophagus [28]. We suggest that
the preferential loss of the 72Pro variant and/or mutations of
72Arg, also seen in our study for colorectal cancer and
colorectal liver metastases, is of biologic significance. Thus,
we tested all tumors for p53 mutations. Indeed, tumors that
had retained the 72Arg allele often carried p53 mutations,
with the ‘‘gain-of-function’’ type occurring with remarkably
high frequency. In contrast, p53 mutations were found only
in a small percentage of LOH-negative tumors in germline
Arg/Pro patients and never in the germline homozygous
Pro/Pro patients. A favored loss of the 72Pro, together with
a selection for mutation in the retained 72Arg, was also
reported by Brooks et al. [12] for squamous cell carcinomas
of the vulva. Their data and ours seem to be consistent with
reports on functionally significant interactions between some
p53 mutants and the p53-related protein p73 in head and
neck cancers [11].
It was reported that both forms of human p53 can
increase the tumorigenicity of NIH 3T3 cells in nude mice
and that 72Arg is more oncogenic in this respect than the
72Pro variant of p53 [29]. Thomas et al. [2] showed that the
72Arg form is a better inducer of transcription because of its
stronger affinity for the TAFII32 and TAFII70 transcrip-
tion factors. Therefore, the prevalence of the homozygous
72Arg variant in cervical cancer might be explained by the
increased susceptibility of p53 to degradation by E6 protein
Figure 3. (A) Two peaks showing the heterozygous status Arg/Pro in the blood (NT) of patient 2; the corresponding tumor (T) shows only the 72Arg peak,
confirming an LOH in this case (#). (B) In accordance with this finding, sequencing analysis of tumor 2 detected the dominance of the mutant adenine allele (CGC
to CAC) at codon 175.
Table 4. Correlation between p53-LOH and p53 Mutations in Colorectal
Tumors and Metastases.
p53-LOH p53 Mutations
 + Total P
 15 7 22
+ 13 21 34 .029
Total 28 28* 56y
*Three p53 mutations were detected in cases where LOH could not be
determined.
yCorrelation was calculated only in cases that were informative for LOH
marker.
Table 5. Correlation between p53 Mutations and Arg/Pro Status in Colorectal
Cancer and Metastases.
p53 Mutations Status at Codon 72
Arg/Arg [n (%)] Arg/Pro [n (%)] Pro/Pro [n (%)]
Primary tumors 22/35 (63) 2/20 (10) 0/6 (0)
Metastases 7/22 (31.6) 0/5 (0) 0/1 (0)
Total 29/57 (50.9) 2/25 (8) 0/7 (0)
P < .001
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of HPV16/18 [9]. Considering colorectal cancer and colorec-
tal liver metastases, HPV infection must be excluded as a
possible reason for the higher frequency of the homozygous
72Arg variant in the tumors. Otherwise, in a recent study,
an enhanced apoptotic potential of the 72Arg variant
caused by its preferential mitochondrial localization and its
greater ubiquination by the E3 ubiquitin ligase MDM2 was
reported [30].
Based on our finding of a significant increase in the 72Arg
variant with Dukes stage, we suggest that 72Arg correlates
with the malignant potential of the tumor. This seems to be
interesting because a similar increase in 72Arg status with
more advanced cases has also been reported in urinary tract
cancers [31] and lung cancer [14]. Furthermore, it is known
that the development of hepatic metastases is largely de-
pendent on certain risk factors, such as diet, and is modu-
lated by different host factors or different colon subsites [32].
Although the number of cases investigated was low, we
found in our group of primary tumors and metastases that
the original location of metastasized tumors was always on
the left (n = 2 sigmoid and n = 4 rectum)—the side of the
highest carcinogenic exposure. Exposure to mutagens may
first promote p53-LOH with preferential loss of the proline
allele; secondly, the remaining Arg allele functions as a
mediator responsible for a progressive genetic instability,
leading to a more malignant potential, including the capa-
bility of invasiveness and metastasization. This is supported
by Wynford-Thomas and Blaydes [33], who developed
the theory that the genotype of the cell plays a major role
in tumor progression and mainly determines the ‘‘choice’’
of further genetic events. Indeed, experiments have dem-
onstrated that the ability of mutant p53 to bind p73, neutralize
p73-induced apoptosis, and transform cells in coopera-
tion with EJ-Ras was enhanced when codon 72 encoded
Arg [11].
The percentage of p53-LOH in our series of colorectal
cancers and liver metastases is in accordance with the data
published in the literature [34]. We found a tendency for distal
tumors to show allelic losses more frequently than proximal
tumors. Our data are in line with Yashiro et al. [35], who
found a higher frequency of p53-LOH in distal tumors without
reaching significance in their small group of 28 colorectal
cancers, so that the authors did not go into this finding.
Eguchi et al. [19] confirmed a significantly higher frequency
of p53 mutations in left-sided carcinomas than in right-sided
carcinomas. We thus confirm the findings that proximal and
distal colon carcinomas differ in their genetic mechanisms
regulating initiation, morphologic variation, and/or progres-
sion [32,34,36,37]. The increased risk for genetic aberrations
reflected as p53-LOH can be attributed to the fact that left-
sided tumors come into contact with carcinogens more
frequently. Here, bowel transit appears to produce a more
prolonged aggression of the colon mucosa than in the right
colon.
In summary, we found a preferential loss of the 72Pro
allele and mutations in the retained 72Arg in colorectal
cancer and liver metastases. When determining the risk for
a specific cancer type, examinations of tumor tissue alone
are problematic because allelic losses remain unmasked
and are not considered. The increase in the frequency of
p53-LOH, together with a higher frequency of 72Arg homo-
zygotes in left-sided colon cancer, may be due to a high
carcinogenic exposure in the distal part of the large intes-
tines. Mutagens may selectively affect the proline allele, and
LOH of the proline allele may be specifically advantageous
for further tumor progression.
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